No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
XFOR X4 Pharmaceuticals
- 1.150
- +0.070+6.48%
Close May 3 16:00 ET
- 1.140
- -0.010-0.87%
Post 19:30 ET
193.13MMarket Cap-2017P/E (TTM)
1.160High1.080Low2.84MVolume1.110Open1.080Pre Close3.19MTurnover2.18%Turnover RatioLossP/E (Static)167.94MShares2.57552wk High3.78P/B149.73MFloat Cap0.57252wk Low--Dividend TTM130.20MShs Float23.930Historical High--Div YieldTTM7.41%Amplitude0.572Historical Low1.121Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $3 to $5.
Buy Rating Affirmed for X4 Pharmaceuticals' Xolremdi on Robust Clinical Efficacy and Favorable Market Strategy
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.(Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it w
UPDATE 1-US FDA Approves X4 Pharmaceuticals' Therapy for Immunodeficiency Disease
X4 Pharmaceuticals Launches XOLREMDI With FDA Approval
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg